Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools

Main inclusion criteria:

• The participants can voluntarily sign informed consent forms
• The participants are male/female over 20 years old.
• The participant is currently undergoing cancer staging based on the previous pathological diagnosis of colorectal cancer
• The participants are confirmed liver metastasis by CT, abdominal ultrasound, MRI, and FDG PET/CT within 30 days before receiving PSMA-PET/CT.
• WHO performance status ≦ 2 points
• The participants can lie on table for two hours during PSMA-PET/CT scanning.

Main exclusion criteria: To improve the accurate interpretation of PMSA-PET imaging and reduce the occurrence of related-drug adverse events, the participants will be excluded by following below criteria.

• The colorectal cancer participants was diagnosed other organs metastases with multiple organ metastases not only the liver.
• The colorectal cancer participants have undergone any treate after diagnosis of liver metastasis.
• The participants have suffered from liver dysfunction such as AST/ALT ratio >2、total bilirubin >1.5 mg/dL within 6 months.
• The participants suffered stage IV chronic kidney disease (eGFR<30 mL/min/1.73 m2) within 6 months.
• The participants suffered acute kidney injury within 6 months.
• The participants suffered trauma or fracture.
• The participants are allergic to any radiopharmaceutical or imaging agent.
• The participants are history of claustrophobia or are inability to remain quiet during the examination.